Summary
Cellular immunologic reactions occurring in the bladder after intravesical treatment with bacillus Calmette-Guérin (BCG) were investigated by flow cytofluorometric analysis of leukocytes present in the urine. Urine specimens from 11 superficial bladder cancer patients were collected before and 5, 24, 48 and 72 h after repeated BCG instillations. Monoclonal antibodies specific for granulocytes, monocytes/macrophages, and T-and B-lymphocytes were used to characterize and quantify leukocyte subpopulations. The total number of cells in urine was found to be 2- to 485-fold increased 24 h after BCG administration. The predominant cell type present was the polymorphonuclear granulocyte, probably representing a defense mechanism against mycobacteria. The main mononuclear leukocytes in urine specimens were monocytes/macrophages and T-lymphocytes, indicating an ongoing immune response in the bladder wall. Although percentages of lymphocytes were low, T- and B-cells could be identified using a selective cell measurement procedure. In conclusion, a clear increase in the numbers of granulocytes, monocytes/macrophages and T-lymphocytes in urine after intravesical BCG administration was demonstrated, indicating local activation of the immune system.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antony VB, Sahn SA, Antony AC, Repine JE (1985) Bacillus Calmette-Guérin-stimulated neutrophils release chemotaxins for monocytes in rabbit pleural spaces and in vitro. J Clin Invest 76:1514
Becker EL (1988) The cytotoxic action of neutrophils on mammalian cells in vitro. Prog Allergy 40:183
Böhle A, Nowc C, Ulmer A, Musehold J, Flad F (1989) Detection of urinary IL-1, IL-2, and TNF after intravesical BCG therapy. Paper presented at conference “New trends in urology”, September 13–16, 1989, University of Nijmegen; (Abstract book p 40)
Davies M (1982) Bacillus Calmette-Guérin as an anti-tumor agent. The interaction with cells of the mammalian immune system. Biochem Biophys Acta 651:143
Debruyne FMJ, Van Der Meijden APM, Geboers ADH, Franssen MPH, Van Leeuwen MJW, Steerenberg PA, De Jong WH, Ruitenberg EJ (1988) BCG-RIVM versus mitomycin intraversical therapy in superficial bladder cancer. First results of a randomized prospective trial. Urology 31 [Suppl]:20
De Jong WH, De Boer EC, Van Der Meijden APM, Vegt P, Steerenberg PA, Debruyne FMJ, Ruitenberg EJ (1990) Presence of interleukin-2 in urine after intravesical treatment of superficial bladder cancer patients with bacillus Calmette-Guérin. Cancer Immunol Immunother 31:182
De Jong WH, Steerenberg PA, Ruitenberg EJ (1987) Bacillus Calmette-Guérin (BCG) and its use for cancer immunotherapy. Res Monogr Immunol 11:283
Guinan P, Shaw M, Ray P (1986) Histopathology of BCG and thiotepa treated bladders. Urol Res 14:211
Haaff EO, Catalona WJ, Ratliff TL (1986) Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Uro 136:970
Haaf EO, Dresner SM, Kelley DR, Ratliff TL, Shapiro A, Catalona WJ (1985) Role of immunotherapy in the prevention of reccurrence and invasion of urothelial bladder tumors: a review. World J Urol 3:76
Holzer TJ, Kizlaitis L, Vachula M, Weaver CW, Andersen BR (1988) Human phagocytic cell responses to Mycobacterium leprae and Mycobacterum bovis Bacillus Calmette-Guérin. J Immunol 141:170
Huland E, Huland H (1989) Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49:5469
Lage JM, Bauer WC, Kelley DR, Ratliff TL, Catalona WJ (1986) Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guérin treatment of superficial bladder cancer. J Urol 135:916
Montgomery LG, Lemon WS (1933) The cellular reaction of the pleura to infection with myobacteria tuberculosis. J Thoracic Surg 2:429
Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116:180
Prescott S, James K, Busuttil A, Hargreave TB, Chisholm GD, Smyth JF (1989) HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol 63:264
Ratliff TL (1989) Mechanisms of action of intravesical BCG for bladder cancer. In: Debruyne FMJ, Denis L, Van Der Meijden APM (eds) BCG in superficial bladder cancer. EORTC Genitourinary group monograph 6. Liss, New York, p 107
Segasothy M, Lau TM, Birch DF, Fairley KF, Kincaid-Smith P (1988) Immunocytologic dissection of the urine sediment using monoclonal antibodies. Am J Clin Pathol 90:961
Stefanini GF, Bercovich E, Mazzeo V, Grigioni WF, Emili E, D'Errico A, Lo Cigno M, Tamagnini N, Mazetti M (1989) Class I and Class II HLA antigen expression by transitional cell carcinoma of the bladder: correlation with T-cell infiltration and BCG treatment. J Urol 141:1449
Van der Meijden APM, De Jong WH, Steerenberg PA, Walvoort HC, De Boer EC, Debruyne FMJ, Ruitenberg EJ (1988) Intravesical BCG administration in the guniea pig. A histomorphological study. Virchows Arch [B] 55:207
Weiner RS, Linn R, Wasjman Z, Hackett RL (1989) Identification of T subpopulation in human bladder washings during a six week course of intravesical BCG (abstract 487). AUA 84th Annual Meeting, May 7–11, 1989, Dallas. J Urol 141:291A
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Boer, E.C., de Jong, W.H., van der Meijden, A.P.M. et al. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. Urol. Res. 19, 45–50 (1991). https://doi.org/10.1007/BF00294021
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00294021